TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML)...
39 insider purchases on record · latest filing 2025-12-23.
Insiders have also filed 4 sale transactions at TCRX.